Which has better valuation and earnings, TNGX or ANL?

Adlai Nortye has lower revenue, but higher earnings than Tango Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 65.81 -$101.59M -$0.85 N/A Adlai Nortye $5M 206.92 -$35.53M N/A N/A

Is TNGX or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Adlai Nortye N/A N/A N/A

Does the media favor TNGX or ANL?

In the previous week, Tango Therapeutics had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Tango Therapeutics' score of 0.89 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ANL or AMLX?

Adlai Nortye has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 206.92 -$35.53M N/A N/A Amylyx Pharmaceuticals $87.37M 39.53 -$144.74M -$1.43 N/A

Is ANL or AMLX more profitable?

Adlai Nortye's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Amylyx Pharmaceuticals N/A -52.92% -48.53%

Which has better valuation & earnings, ELVN or ANL?

Adlai Nortye has higher revenue and earnings than Enliven Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Adlai Nortye $5M 206.92 -$35.53M N/A N/A

Is ELVN or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Adlai Nortye N/A N/A N/A

Does the media favor ELVN or ANL?

In the previous week, Enliven Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Enliven Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Enliven Therapeutics' score of 0.49 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ABCL or ANL?

Adlai Nortye has lower revenue, but higher earnings than AbCellera Biologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbCellera Biologics $75.13M 49.89 -$146.41M -$0.54 N/A Adlai Nortye $5M 206.92 -$35.53M N/A N/A

Does the media favor ABCL or ANL?

In the previous week, AbCellera Biologics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat AbCellera Biologics' score of 0.76 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VKTX or ANL?

Adlai Nortye has higher revenue and earnings than Viking Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Adlai Nortye $5M 206.92 -$35.53M N/A N/A

Is VKTX or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Adlai Nortye N/A N/A N/A

Does the media favor VKTX or ANL?

In the previous week, Viking Therapeutics had 26 more articles in the media than Adlai Nortye. MarketBeat recorded 29 mentions for Viking Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Viking Therapeutics' score of 0.43 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 11 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adlai Nortye (ANL) Competitors

$16.07 -0.54 (-3.22%)

As of 01:00 PM Eastern

Compare

ANL vs. TNGX, AMLX, ELVN, ABCL, and VKTX

Should you buy Adlai Nortye stock or one of its competitors? Adlai Nortye's main competitors and comparable companies include Tango Therapeutics (TNGX), Amylyx Pharmaceuticals (AMLX), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adlai Nortye compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Tango Therapeutics had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Tango Therapeutics' score of 0.89 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adlai Nortye has lower revenue, but higher earnings than Tango Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.81	-$101.59M	-$0.85	N/A
Adlai Nortye	$5M	206.92	-$35.53M	N/A	N/A

Tango Therapeutics currently has a consensus price target of $43.46, suggesting a potential upside of 78.51%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 83.63%. Given Adlai Nortye's higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adlai Nortye's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Adlai Nortye	N/A	N/A	N/A

Summary

Tango Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to Amylyx Pharmaceuticals?

Adlai Nortye (NASDAQ:ANL) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adlai Nortye's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Adlai Nortye currently has a consensus target price of $29.50, indicating a potential upside of 83.63%. Amylyx Pharmaceuticals has a consensus target price of $38.86, indicating a potential upside of 25.35%. Given Adlai Nortye's higher possible upside, equities research analysts plainly believe Adlai Nortye is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Adlai Nortye had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 3 mentions for Adlai Nortye and 0 mentions for Amylyx Pharmaceuticals. Adlai Nortye's average media sentiment score of 0.92 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Overall Sentiment
Adlai Nortye	Positive
Amylyx Pharmaceuticals	Neutral

Adlai Nortye has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

Adlai Nortye has higher earnings, but lower revenue than Amylyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	206.92	-$35.53M	N/A	N/A
Amylyx Pharmaceuticals	$87.37M	39.53	-$144.74M	-$1.43	N/A

Summary

Adlai Nortye beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Adlai Nortye's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Enliven Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Enliven Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Enliven Therapeutics' score of 0.49 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Enliven Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Adlai Nortye	$5M	206.92	-$35.53M	N/A	N/A

Enliven Therapeutics presently has a consensus price target of $75.00, suggesting a potential upside of 63.86%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 83.63%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enliven Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Summary

Adlai Nortye beats Enliven Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

AbCellera Biologics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Adlai Nortye has lower revenue, but higher earnings than AbCellera Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	49.89	-$146.41M	-$0.54	N/A
Adlai Nortye	$5M	206.92	-$35.53M	N/A	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adlai Nortye has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. Adlai Nortye's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Adlai Nortye	N/A	N/A	N/A

In the previous week, AbCellera Biologics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat AbCellera Biologics' score of 0.76 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics presently has a consensus price target of $12.83, suggesting a potential upside of 4.98%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 83.63%. Given Adlai Nortye's higher probable upside, analysts clearly believe Adlai Nortye is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Adlai Nortye beats AbCellera Biologics on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Adlai Nortye's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Viking Therapeutics had 26 more articles in the media than Adlai Nortye. MarketBeat recorded 29 mentions for Viking Therapeutics and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Viking Therapeutics' score of 0.43 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	11 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Viking Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Adlai Nortye	$5M	206.92	-$35.53M	N/A	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Viking Therapeutics currently has a consensus price target of $99.67, suggesting a potential upside of 148.63%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 83.63%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Viking Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$3.89B	$7.20B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	N/A	14.40	274.68	25.72
Price / Sales	206.92	1,367.73	643.53	85.59
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	-76.50	15.24	10.43	6.31
Net Income	-$35.53M	-$22.82M	$3.48B	$359.73M
7 Day Performance	3.51%	-0.24%	0.68%	1.56%
1 Month Performance	17.26%	-6.03%	-3.26%	-3.48%
1 Year Performance	797.49%	34.79%	16.17%	5.68%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	2.3494 of 5 stars	$16.07 -3.2%	$29.50 +83.6%	+882.2%	$1.03B	$5M	N/A	109
TNGX Tango Therapeutics	2.865 of 5 stars	$23.35 -2.3%	$43.46 +86.1%	+242.7%	$3.94B	$62.38M	N/A	137
AMLX Amylyx Pharmaceuticals	3.5075 of 5 stars	$32.63 -1.6%	$38.86 +19.1%	+147.9%	$3.64B	$87.37M	N/A	136
ELVN Enliven Therapeutics	2.2962 of 5 stars	$49.12 -7.9%	$75.00 +52.7%	+141.9%	$3.60B	N/A	N/A	67	Insider Trade High Trading Volume
ABCL AbCellera Biologics	1.6249 of 5 stars	$11.67 +2.3%	$12.83 +10.0%	+161.9%	$3.58B	$75.13M	N/A	562

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. TNGX, AMLX, ELVN, ABCL, and VKTX

How does Adlai Nortye compare to Tango Therapeutics?

Summary

How does Adlai Nortye compare to Amylyx Pharmaceuticals?

Summary

How does Adlai Nortye compare to Enliven Therapeutics?

Summary

How does Adlai Nortye compare to AbCellera Biologics?

Summary

How does Adlai Nortye compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. TNGX, AMLX, ELVN, ABCL, and VKTX

How does Adlai Nortye compare to Tango Therapeutics?

Does the media favor TNGX or ANL?

Which has more volatility and risk, TNGX or ANL?

Do insiders & institutionals hold more shares of TNGX or ANL?

Which has better valuation and earnings, TNGX or ANL?

Do analysts rate TNGX or ANL?

Is TNGX or ANL more profitable?

Summary

How does Adlai Nortye compare to Amylyx Pharmaceuticals?

Do insiders & institutionals have more ownership in ANL or AMLX?

Is ANL or AMLX more profitable?

Do analysts recommend ANL or AMLX?

Does the media prefer ANL or AMLX?

Which has more volatility & risk, ANL or AMLX?

Which has better earnings and valuation, ANL or AMLX?

Summary

How does Adlai Nortye compare to Enliven Therapeutics?

Is ELVN or ANL more profitable?

Does the media favor ELVN or ANL?

Which has better valuation & earnings, ELVN or ANL?

Do analysts prefer ELVN or ANL?

Do insiders and institutionals hold more shares of ELVN or ANL?

Which has more volatility and risk, ELVN or ANL?

Summary

How does Adlai Nortye compare to AbCellera Biologics?

Which has more volatility and risk, ABCL or ANL?

Which has higher valuation and earnings, ABCL or ANL?

Do institutionals and insiders believe in ABCL or ANL?

Is ABCL or ANL more profitable?

Does the media favor ABCL or ANL?

Do analysts rate ABCL or ANL?

Summary

How does Adlai Nortye compare to Viking Therapeutics?

Is VKTX or ANL more profitable?

Does the media favor VKTX or ANL?

Which has preferable earnings and valuation, VKTX or ANL?

Do institutionals & insiders have more ownership in VKTX or ANL?

Which has more volatility & risk, VKTX or ANL?

Do analysts recommend VKTX or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools